Stand strong against the flu

HELP YOUR PATIENTS

STAND STRONG AGAINST THE FLU WITH THE PROTECTION OF AFLURIA

LEARN MORE

AFLURIA OFFERS YOU THE FLEXIBILITY

OF 2 PRODUCT PRESENTATIONS

Pre-filled_syringe

PRESERVATIVE-FREE,
SINGLE-USE, PRE-FILLED SYRINGE

10-dose multi-dose vial with peel-off labels

10-DOSE MULTI-DOSE VIAL
WITH PEEL-OFF LABELS* *CONTAINS THIMEROSAL AS A PRESERVATIVE

LEARN MORE

AFLURIA IS THE FIRST AND ONLY FLU VACCINE

FDA APPROVED FOR ADMINISTRATION WITH THE

PHARMAJET® STRATIS® NEEDLE-FREE INJECTOR

PharmaJet Stratis Needle-Free Injector LEARN MORE

SEQIRUS IS A TRUSTED VACCINE MANUFACTURER

WITH NEARLY 50 YEARS OF EXPERIENCE

LEARN MORE
seqirus

The product information presented on this site is for U.S. residents only. Afluria® Quadrivalent, Afluria®, and Seqirus are trademarks of Seqirus UK Limited or its affiliates. PharmaJet® and Stratis® are registered trademarks of PharmaJet Inc. Manufactured by: Seqirus Pty Ltd Parkville, Victoria, 3052, Australia Distributed by: Seqirus USA Inc. 25 Deforest Avenue, Summit, NJ 07901, USA © 2017 Seqirus USA Inc. www.seqirus-us.com MCC Code, Month 2017

OPEN

Important Safety Information for Afluria Quadrivalent and Afluria

AFLURIA® QUADRIVALENT (Influenza Vaccine) Important Safety Information

INDICATION
AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. AFLURIA QUADRIVALENT is approved for use in individuals 5 years of age and older.
CONTRAINDICATIONS
  • Severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine.
WARNINGS AND PRECAUTIONS
  • If Guillain-Barré Syndrome (GBS) has occurred within 6 weeks of previous influenza vaccination, the decision to give AFLURIA QUADRIVALENT should be based on careful consideration of the potential benefits and risks.
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.
  • Immunocompromised persons may have a diminished immune response to AFLURIA QUADRIVALENT.
ADVERSE REACTIONS
  • In adults 18 through 64 years, the most commonly reported injection-site adverse reaction when administered by needle and syringe was pain (≥40%). The most common systemic adverse events were myalgia and headache (≥20%).
  • In adults 65 years of age and older, the most commonly reported injection-site adverse reaction when administered by needle and syringe was pain (≥20%). The most common systemic adverse event was myalgia (≥10%).
  • In children 5 through 8 years, the most commonly reported injection-site adverse reactions when administered by needle and syringe were pain (≥50%), redness and swelling (≥10%). The most common systemic adverse event was headache (≥10%).
  • In children 9 through 17 years, the most commonly reported injection-site adverse reactions when administered by needle and syringe were pain (≥50%), redness and swelling (≥10%). The most common systemic adverse events were headache, myalgia, and malaise and fatigue (≥10%).

The safety experience with AFLURIA (trivalent formulation) is relevant to AFLURIA QUADRIVALENT because both vaccines are manufactured using the same process and have overlapping compositions:

  • In adults 18 through 64 years of age, the most commonly reported injection-site adverse reactions with AFLURIA (trivalent formulation) when administered by the PharmaJet Stratis Needle-Free Injection System were tenderness (≥80%), swelling, pain, redness (≥60%), itching (≥20%) and bruising (≥10%). The most common systemic adverse events were myalgia, malaise (≥30%), and headache (≥20%).

Please see accompanying full Prescribing Information for AFLURIA QUADRIVALENT.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.


AFLURIA® (Influenza Vaccine) Important Safety Information

INDICATION

AFLURIA is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B present in the vaccine. AFLURIA is approved for use in persons 5 years of age and older.

CONTRAINDICATIONS
  • Severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine.
WARNINGS AND PRECAUTIONS
  • Administration of CSL’s 2010 Southern Hemisphere influenza vaccine has been associated with increased rates of fever and febrile seizures in children predominantly below the age of 5 years as compared to previous years. Febrile events were also observed in children 5 through 8 years of age.
  • If Guillain-Barré Syndrome (GBS) has occurred within 6 weeks of previous influenza vaccination, the decision to give AFLURIA should be based on careful consideration of the potential benefits and risks.
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.
  • Immunocompromised persons may have a diminished immune response to AFLURIA.
ADVERSE REACTIONS
  • In children five through 17 years of age, the most common injection-site adverse reactions when administered by needle and syringe were pain (≥60%), redness (≥20%) and swelling (≥10%). The most common systemic adverse events were headache, myalgia (≥20%), irritability, malaise and fever (≥10%).
  • In adults 18 through 64 years of age, the most common injection-site adverse reactions when administered by needle and syringe were tenderness (≥60%), pain (≥40%), swelling (≥20%), and redness, itching (≥10%). The most common systemic adverse events were muscle aches (≥30%) headache and malaise (≥20%).
  • In adults 18 through 64 years of age, the most common injection-site adverse reactions when administered by the PharmaJet Stratis Needle-Free Injection System up to 7 days post-vaccination were tenderness (≥80%), swelling, pain, redness (≥60%), itching (≥20%) and bruising (≥10%). The most common systemic adverse events within this period were myalgia, malaise (≥30%), and headache (≥20%).
  • In adults 65 years of age and older, when administered by needle and syringe the most common injection-site adverse reactions were tenderness (≥30%) and pain (≥10%). No systemic adverse events occurred in ≥10% of subjects in this age group.

Please see accompanying full Prescribing Information for AFLURIA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

AFLURIA is a registered trademark of Seqirus UK Limited or its affiliates.